183 related articles for article (PubMed ID: 17210164)
21. Monitoring of human populations for early markers of cadmium toxicity: a review.
Fowler BA
Toxicol Appl Pharmacol; 2009 Aug; 238(3):294-300. PubMed ID: 19433102
[TBL] [Abstract][Full Text] [Related]
22. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions.
Jurisicova A; Jurisica I; Kislinger T
Expert Rev Proteomics; 2008 Aug; 5(4):551-60. PubMed ID: 18761466
[TBL] [Abstract][Full Text] [Related]
23. Serum biomarker profiling in cancer studies: a question of standardisation?
Matharoo-Ball B; Miles AK; Creaser CS; Ball G; Rees R
Vet Comp Oncol; 2008 Dec; 6(4):224-47. PubMed ID: 19178682
[TBL] [Abstract][Full Text] [Related]
24. 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases.
Sheta EA; Appel SH; Goldknopf IL
Expert Rev Proteomics; 2006 Feb; 3(1):45-62. PubMed ID: 16445350
[TBL] [Abstract][Full Text] [Related]
25. Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery.
Hu S; Yen Y; Ann D; Wong DT
Drug Discov Today; 2007 Nov; 12(21-22):911-6. PubMed ID: 17993408
[TBL] [Abstract][Full Text] [Related]
26. Proteomics as a tool for the modelling of biological processes and biomarker development in nutrition research.
de Roos B; McArdle HJ
Br J Nutr; 2008 Jun; 99 Suppl 3():S66-71. PubMed ID: 18598591
[TBL] [Abstract][Full Text] [Related]
27. Proteomics: new technologies and clinical applications.
Latterich M; Abramovitz M; Leyland-Jones B
Eur J Cancer; 2008 Dec; 44(18):2737-41. PubMed ID: 18977654
[TBL] [Abstract][Full Text] [Related]
28. Prevalidation of potential protein biomarkers in toxicology using iTRAQ reagent technology.
Glückmann M; Fella K; Waidelich D; Merkel D; Kruft V; Kramer PJ; Walter Y; Hellmann J; Karas M; Kröger M
Proteomics; 2007 May; 7(10):1564-74. PubMed ID: 17443845
[TBL] [Abstract][Full Text] [Related]
29. Current proteomic analysis and post-translational modifications of biomarkers in human lung cancer materials.
Sinchaikul S; Hongsachart P; Sriyam S; Tantipaiboonwong P; Phutrakul S; Chen ST
Chang Gung Med J; 2008; 31(5):417-30. PubMed ID: 19097588
[TBL] [Abstract][Full Text] [Related]
30. Proteomics, nanotechnology and molecular diagnostics.
Johnson CJ; Zhukovsky N; Cass AE; Nagy JM
Proteomics; 2008 Feb; 8(4):715-30. PubMed ID: 18297650
[TBL] [Abstract][Full Text] [Related]
31. Approaches for systematic proteome exploration.
Falk R; Ramström M; Ståhl S; Hober S
Biomol Eng; 2007 Jun; 24(2):155-68. PubMed ID: 17376740
[TBL] [Abstract][Full Text] [Related]
32. Gaucher disease: a model disorder for biomarker discovery.
Boot RG; van Breemen MJ; Wegdam W; Sprenger RR; de Jong S; Speijer D; Hollak CE; van Dussen L; Hoefsloot HC; Smilde AK; de Koster CG; Vissers JP; Aerts JM
Expert Rev Proteomics; 2009 Aug; 6(4):411-9. PubMed ID: 19681676
[TBL] [Abstract][Full Text] [Related]
33. Proteomic biomarker discovery for the monogenic disease cystic fibrosis.
Penque D
Expert Rev Proteomics; 2007 Apr; 4(2):199-209. PubMed ID: 17425456
[TBL] [Abstract][Full Text] [Related]
34. Complementary gene and protein expression studies and integrative approaches in toxicogenomics.
Merrick BA; Madenspacher JH
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):189-94. PubMed ID: 15992845
[TBL] [Abstract][Full Text] [Related]
35. Omics in mechanistic and predictive toxicology.
Singh S; Singhal NK; Srivastava G; Singh MP
Toxicol Mech Methods; 2010 Sep; 20(7):355-62. PubMed ID: 20082572
[TBL] [Abstract][Full Text] [Related]
36. [Biomarkers for toxicity and metabolic abnormalities of the main severe poisonings. Clinical and toxicologic symptoms. Conservative determination].
Goullé JP; Lhermitte M; Bartholi M; Boyer JC; Capolaghi B; Charlier C; Danel V; Desch G; Feuillu A; Flouvat B; Mathieu D; Nisse P; Sadeg N; Szymanowicz A;
Ann Biol Clin (Paris); 2003; 61(4):421-33. PubMed ID: 12915351
[TBL] [Abstract][Full Text] [Related]
37. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology.
Coen M; Holmes E; Lindon JC; Nicholson JK
Chem Res Toxicol; 2008 Jan; 21(1):9-27. PubMed ID: 18171018
[TBL] [Abstract][Full Text] [Related]
38. Proteomics approaches to urologic diseases.
Liu BC; Ehrlich JR
Expert Rev Proteomics; 2006 Jun; 3(3):283-96. PubMed ID: 16771701
[TBL] [Abstract][Full Text] [Related]
39. Toxicogenomics and systems toxicology: aims and prospects.
Waters MD; Fostel JM
Nat Rev Genet; 2004 Dec; 5(12):936-48. PubMed ID: 15573125
[TBL] [Abstract][Full Text] [Related]
40. Combinatorial biomarkers: From early toxicology assays to patient population profiling.
Koop R
Drug Discov Today; 2005 Jun; 10(11):781-8. PubMed ID: 15922936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
